Related Experiment Videos
Managing the patient at risk for a second stroke
1State University of New York DownState College of Medicine, New York, USA. michaelwebermd@cs.com
Summary
Aggressive antihypertensive therapy, particularly angiotensin II receptor blockers (ARBs), effectively reduces stroke risk. ARBs may offer greater cerebrovascular protection than expected from blood pressure reduction alone.
Area of Science:
- Cardiology
- Neurology
- Pharmacology
Background:
- Cerebrovascular disease is a leading global cause of mortality, with increasing prevalence due to demographic shifts.
- Antihypertensive therapy, even with modest blood pressure reductions, significantly lowers stroke risk, benefiting even non-hypertensive individuals.
- Comparative trials highlight varying impacts of antihypertensive drug classes on cerebrovascular disease incidence, influencing therapeutic decisions for stroke risk factors.
Purpose of the Study:
- To investigate the differential effects of antihypertensive drug classes on cerebrovascular disease, focusing on the renin-angiotensin system.
- To evaluate the specific role of angiotensin II receptor blockers (ARBs) in reducing stroke risk beyond their blood pressure-lowering effects.
- To explore the clinical relevance of renin-angiotensin system receptor subtypes and the impact of morning blood pressure control on stroke incidence.
Main Methods:
- Analysis of comparative clinical trials examining antihypertensive therapies and their effects on cerebrovascular events.
- Review of evidence regarding angiotensin II receptor blockers (ARBs) versus angiotensin converting enzyme inhibitors (ACEIs) in stroke prevention.
- Consideration of preclinical data on angiotensin II receptor subtypes (AT1 and AT2) and ongoing large-scale trials (PRoFESS, ONTARGET).
Main Results:
- Evidence suggests ARBs may reduce first stroke risk more than expected solely from blood pressure reduction.
- The MOSES study indicated ARBs provide additional cardiovascular and cerebrovascular protection in hypertensive patients with prior stroke, beyond blood pressure control.
- Preclinical data suggest differential effects of AT1 and AT2 receptor activation, though clinical significance remains unknown.
Conclusions:
- Antihypertensive therapy is crucial for reducing cerebrovascular disease burden.
- ARBs show potential for superior stroke risk reduction compared to other antihypertensives, possibly through mechanisms beyond blood pressure lowering.
- Further research through ongoing trials is essential to clarify the role of specific drug classes and receptor pathways in cerebrovascular protection.